Literature DB >> 19834871

Pioglitazone induced reversible pancytopenia.

F Karakurt1, A Kargili, B Kasapoglu.   

Abstract

Pioglitazone is used to improve insulin sensitivity in type 2 diabetes. This group of drugs is usually well tolerated; however, their use may be associated with several adverse effects including edema, weight gain, macular edema and heart failure. Herein we report a patient who developed pancytopenia on the 7th day of oral pioglitazone treatment for the control of diabetes mellitus and fully recovered 6 days after the cessation of this drug. To the best of our knowledge this is the first reported case of pancytopenia induced by pioglitazone therapy. J. A. Barth Verlag in Georg Thieme Verlag KG Stuttgart. New York.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19834871     DOI: 10.1055/s-0029-1234065

Source DB:  PubMed          Journal:  Exp Clin Endocrinol Diabetes        ISSN: 0947-7349            Impact factor:   2.949


  3 in total

1.  Rosiglitazone Promotes Bone Marrow Adipogenesis to Impair Myelopoiesis under Stress.

Authors:  Wenyi Lu; Weimin Wang; Shujuan Wang; Yonghuai Feng; Kaiyan Liu
Journal:  PLoS One       Date:  2016-02-19       Impact factor: 3.240

2.  A pilot dose finding study of pioglitazone in autistic children.

Authors:  Lucia Capano; Annie Dupuis; Jessica Brian; Deepali Mankad; Lisa Genore; Rianne Hastie Adams; Sharon Smile; Toni Lui; Dina Odrobina; Jane A Foster; Evdokia Anagnostou
Journal:  Mol Autism       Date:  2018-11-26       Impact factor: 7.509

3.  The association between different hypoglycemic regimens and postoperative diabetic macular edema after vitrectomy in the Japanese patients with proliferative diabetic retinopathy.

Authors:  Chunyan Lei; Yun Zhang; Meixia Zhang
Journal:  Front Endocrinol (Lausanne)       Date:  2022-07-22       Impact factor: 6.055

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.